Hemoadsorption (CytoSorb®) in management of Cytokine Storm - Implication in COVID-19 pandemic.

Harish Mallapura Maheshwarappa¹, Shreedhar Joshi¹, Robert Premkumar², Shivangi Mishra¹, Shiva Prasad¹, and Muralidhar Kanchi¹

March 07, 2024

Abstract

Background: Sepsis-related deaths contribute up to 20% of all global deaths, with the highest-burden from sub-Saharan Africa and Southeast Asia. Cytokines are the mediators of organ dysfunction in systemic inflammatory response syndrome (SIRS) across varied aetiologies, including sepsis. The imbalance of pro and anti-inflammatory cytokines continues to be the crux of the pathophysiology of organ dysfunction in septic shock. Therapies to treat cytokines either by antagonizing them or filtering them out of the body are evolving. Hemoadsorption is a process of filtering out cytokines and other metabolites involved in SIRS by surface adsorption. Methods: We searched for terms – Hemoadsorption; CytoSorb; in PubMed. We enrolled manuscripts with patients at Indian Centres for review. We extend our review of cytokine storm in COVID-19 and the utility of CytoSorb as an adjuvant in the management of septic shock in COVID-19. Results: Severe acute respiratory syndrome coronavirus -2 (SARS-CoV-2) infection causing COVID-19 (Corona Virus disease - 2019) pandemic has affirmed cytokine storm as the principle pathology causing morbidity and mortality. Management strategies are mostly supportive since specific anti-viral therapy is still in the incipient stage. Cytokine adsorption is being used across most western countries in COVID-19 septic shock. Conclusion: COVID-19 with cytokine storm as its main pathology is a suitable substrate for the use of CytoSorb. COVID-19 patients with elevated cytokine levels can be offered CytoSorb® hemoadsorption along with other supportive therapies.

Hosted file


main article.docx available at https://authorea.com/users/732024/articles/710671-hemoadsorption-cytosorb-in-management-of-cytokine-storm-implication-in-covid-19-pandemic

¹Narayana Hrudayalaya Foundation


²Mazumdar Shaw Medical Centre


Membrane Filter Dialysis works on the principles of the diffusion of solutes and ultrafiltration of fluid across a semi-permeable membrane. Dialysate Full Blood Dialysable Substances e.g. Potassitum Non-Dialyzables Substances e.g. II.6, II.10, TNF-α Albumin = Transport device for lipophilic substances lipophilic substances


Concentration dependent removal



CytoSorb adsorption spectrum







Clinical Variables	Severity Score			Patient Score (Take highest score	Patient Score to Initiate Cytosorb		
	1	2	3	of any variable in each segment)	<8		
Hemodynamic Parameter						8-13	>13
MAP	>70 mmHg With or without vasopressor support	> 65 mmHg High dose single Vasopressors (0.3mcg/ml)	> 65 mmHg High dose of multip l e Vasopressors		Early	Definite	Late
Septic Shock	< 24hrs	24 – 48hrs	> 48hrs			_	
Renal Parameter					i		
Acute o l iguria	< 0.5 mL/kg/h for 6 hours	< 0.5 mL/kg/h for 12 hours or longer	< 0,3 mL/kg/h for 24 hours or anuria for 12 hrs		If patient is	1	1
S. Creatinine	Increase to > 1.5 fold	Increase to > 2 fold	> 4 mg/dL or greater				Patient might
RRT	Not on RRT	On RRT < 24 hrs	On RRT > 24 hrs				
Respiratory Parameter					hemodynamically	Ideal time to	lead into
Arterial hypoxemia	PaO ₂ /FiO ₂ < 300	PaO ₂ /FiO ₂ < 200	PaO _z /FiO _z < 100	1	unstable or developed an	start CytoSorb without any	refractory stag where
Mechanical Ventilation	Not Required	May require	High PEEP				
Lab Parameters					organ dysfunction,	further delay to	aggressive
S, Lactate PCT CRP	< 2 mmol < 1ng/ml <100 mg/ dl	2- 3.9 mmol 1-3 ng/ml 100 – 200 mg/ dl	> 4 mmol > 3 ng/ml > 200 mg/ dl		start counselling for Therapy	achieve therapy goals	CytoSorb Therapy might
Sepsis Scores				ĺ	Initiation		be required
SOFA Score OR	< 8	8 - 12	>12]			
qSOFA APACHE 2	< 1 < 20	1-2 20 - 25	> 2 > 25				
THE PARTY OF THE P	120	20-25	- 25	I	J]		
			Total Score				